Loss of productivity among commercially insured patients with pulmonary arterial hypertension in the United States [0.03%]
美国商业保险肺动脉高压患者劳动生产力的损失
Anna Watzker,Christine Ferro,Gabriela Dieguez et al.
Anna Watzker et al.
Background: Despite advances in treatment, pulmonary arterial hypertension (PAH) remains a progressive condition with the onset of disease often in working-aged adults, leading to substantial economic burden and increased...
Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non-small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparison [0.03%]
帕博利尤单抗联合化疗与西米普利尤单抗联合化疗用于一线治疗转移性非小细胞肺癌的性价比分析：基于匹配调整间接比较法的美国支付方视角
Danmeng Huang,Ying Zhang,Riddhi A Babel et al.
Danmeng Huang et al.
Aim: Recent clinical guidelines recommend pembrolizumab plus chemotherapy and cemiplimab plus chemotherapy as key first-line treatment options for metastatic non-small cell lung cancer (mNSCLC). We evaluated the cost-effe...
Comparative Study
Journal of medical economics. 2026 Dec;29(1):889-908. DOI:10.1080/13696998.2026.2639229 2026
Real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy in inpatient versus outpatient settings [0.03%]
CAR-T细胞治疗复发/难治多发性骨髓瘤住院与门诊患者的医疗资源利用和临床结局分析
Murali Janakiram,Lin Fan,Sabyasachi Ghosh et al.
Murali Janakiram et al.
Background: Ciltacabtagene autoleucel (cilta-cel) has demonstrated remarkable efficacy in relapsed or refractory multiple myeloma (RRMM). Outpatient (OP) administration of cilta-cel is increasingly used to improve access ...
The full value of mRNA seasonal influenza and endemic-stage COVID-19 combination vaccines: a taxonomy [0.03%]
mRNA季节性流感和地方流行期COVID-19联合疫苗的全部价值：分类学
J P Sevilla,Joseph S Knee,Daria Burnes et al.
J P Sevilla et al.
Aims: Seasonal influenza and COVID-19 pose significant ongoing threats to global health. Vaccination remains central to their prevention. Messenger RNA combination influenza and COVID-19 vaccines (mRNA combo vaccines) are...
P Petrou,Olga Pitsillidou,Constantinos Petrou et al.
P Petrou et al.
Employment and productivity losses from cervical spinal cord injury: a 7-year nationwide cohort study in Taiwan, 2012-2018 [0.03%]
2012-2018年台湾颈椎脊髓损伤患者劳动参与及生产率损失的全国性队列研究
Wei-Ming Wang,Jung-Der Wang,Fuhmei Wang et al.
Wei-Ming Wang et al.
Objective: To investigate the extent to which employment and productivity losses could be prevented by mitigating cervical spinal cord injury (SCI) and concurrent traumatic brain injury (TBI) in Taiwan. ...
Bleeding rates, healthcare utilization, and costs among patients with hemophilia a without inhibitors treated with concomitant octocog alfa or extended half-life factor VIII while on emicizumab prophylaxis [0.03%]
在emicizumab预防治疗期间联合使用八因子或长效八因子治疗不含抑制物的甲型血友病患者的出血率、医疗保健利用情况和费用
Caitlin Montcrieff,Jorge Caicedo,Alicia Cerretani et al.
Caitlin Montcrieff et al.
Aim: Emicizumab has changed prophylactic treatment for HA, but the need for FVIII replacement still exists for the treatment of breakthrough bleeds, perioperative management, and participation in high-risk activities/spor...
Real-world clinical, safety, and economic evaluation of infliximab biosimilar adoption for crohn's disease [0.03%]
真实世界中英夫利西单抗类似药治疗克罗恩病的临床、安全和经济评估
Jihao Shi,Yipeng Pan,Qian Cao et al.
Jihao Shi et al.
Background: Biosimilar infliximab (B-IFX) offers a lower-cost alternative to originator infliximab (O-IFX) for treating Crohn's disease (CD), but real-world data on comparative effectiveness and economic impact in China r...
Analysis of healthcare resource utilization before and after initiation of maribavir for cytomegalovirus treatment [0.03%]
分析马利巴韦治疗巨细胞病毒前后的医疗资源利用情况
Camille N Kotton,Megan Richards,Nicole Princic et al.
Camille N Kotton et al.
Aim: This retrospective observational cohort study aimed to assess healthcare utilization (HCRU) and costs before and after initiation of treatment with maribavir using a United States (US) administrative claims database ...
Observational Study
Journal of medical economics. 2026 Dec;29(1):799-808. DOI:10.1080/13696998.2026.2640810 2026
Economic value of lost productivity attributable to premature cancer mortality and morbidity across Europe [0.03%]
欧洲癌症死亡和致病造成的经济损失评估
Agnes Brandtmüller,Anne Meiwald,Peter Toth et al.
Agnes Brandtmüller et al.
Background: Cancer imposes a substantial clinical and economic burden across Europe. This analysis estimated the lost productivity cost of the five cancer types with the highest premature mortality and five cancer types w...